Abstract
We studied the effect of complete response (CR) among 126 consecutive patients who underwent stem cell transplantation (SCT) for myeloma. The CR rate with SCT was 33%. Median overall survival (OS) from diagnosis of myeloma was 56 months. OS following SCT was 22 months. Progression-free survival (PFS) was 12 months. OS was not different between patients who achieved CR and those who did not, median survival 25 vs 24 months, P = 0.5. Corresponding median times for PFS were 15 and 11 months, P = 0.2. The plasma cell labeling index (PCLI) was high (⩾1%) in 36% (high risk group) and was associated with poor OS and PFS (P < 0.001). Achieving CR did not influence OS or PFS in either the high or the low risk group. In contrast, OS and PFS were significantly influenced by high PCLI both in patients who achieved CR and those who did not. OS was poor (<30 months) in high risk patients regardless of CR status and in low risk patients who did not achieve CR, compared to low risk patients achieving CR (57 months), making them candidates for novel post-transplant treatment options. Outcome following SCT is dependent more on biological variables such as the PCLI than on CR status. Bone Marrow Transplantation (2000) 26, 979–983.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bataille R, Harousseau JL . Multiple myeloma New Engl J Med 1997 336: 1657–1664
Greenlee RT, Murray T, Bolden S, Wingo PA . Cancer statistics, 2000 CA Cancer J Clin 2000 50: 7–33
Myeloma Trialists’ Collaborative Group . Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials J Clin Oncol 1998 16: 3832–3842
Kovacsovics T, Delaly A . Intensive treatment strategies in myeloma Semin Hematol 1997 34: 49–60
Alexanian R, Dimopoulos M . The treatment of multiplemyeloma New Engl J Med 1994 330: 484–489
Oken MM, Harrington DP, Abramson N et al. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479 Cancer 1997 79: 1561–1567
Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome New Engl J Med 1996 335: 91–97
Barlogie B, Jagannath S, Epstein J et al. Biology and therapy of multiple myeloma in 1996 Semin Hematol 1997 34: 67–72
Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 1999 93: 55–65
Oivanen TM, Kellokumpu-Lehtinen P, Koivista A-M et al. Response level and survival after conventional chemotherapy for multiple myeloma: a Finnish Leukaemia group study Eur J Haematol 1999 62: 109–116
Kyle RA, Leong T, Oken MM et al. The effect of complete response (CR) on survival in an ECOG phase III trial for multiple myeloma Blood 1998 92: (Suppl. 1) 319a (Abstr. 1310)
Rajkumar SV, Greipp PR . Prognostic factors in multiple myeloma Hematol Oncol Clin North Am 1999 13: 1295–1314
Greipp PR, Lust JA, O'Fallon WM et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma Blood 1993 81: 3382–3387
ISCN Mitelman F (ed). An International System for Human Cytogenetics Nomenclature S Karger: 1995 Basel: 1995
Spurbeck JL, Carlson RO, Allen JE, Dewald GW . Culturing and robotic harvesting of bone marrow, lymph nodes, peripheral blood, fibroblasts, and solid tumors with in situ techniques Cancer Genet Cytogenet 1988 32: 59–66
Witzig TE, Gonchoroff NJ, Katzmann JA et al. Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies J Clin Oncol 1988 6: 1041–1046
Kaplan E, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481
Cox DR . Regression models and life tables JR Stat Soc (B) 1972 34: 187–202
Anderson JR, Cain KC, Gelber RD . Analysis of survival by tumor response J Clin Oncol 1983 1: 710–719
Tricot G, Sawyer JR, Jagannath S et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants J Clin Oncol 1997 15: 2659–2666
Attal M, Harousseau JL . Standard therapy versus autologous transplantation in multiple myeloma Hematol Oncol Clin North Am 1997 11: 133–146
Alexanian R, Dimopoulos M, Smith T et al. Limited value of myeloablative therapy for late multiple myeloma Blood 1994 83: 512–516
Fermand JP, Ravaud P, Chevret S et al. Early versus late high dose therapy (HDT) and autologous peripheral blood stem cell transplantation in multiple myeloma (MM): results of a prospective randomized trial Blood 1996 88: (Suppl. 1) 685a (Abstr. 2730)
Acknowledgements
Drs Rajkumar and Fonseca are Leukemia and Lymphoma Society Translational Research Awardees. This work was also supported in part by CA 62242 and CA 85818 from the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Dr Rajkumar is also supported by the Judith and George Goldman Foundation Fighting Catastrophic Diseases.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rajkumar, S., Fonseca, R., Dispenzieri, A. et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 26, 979–983 (2000). https://doi.org/10.1038/sj.bmt.1702640
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702640
Keywords
This article is cited by
-
Association of response endpoints with survival outcomes in multiple myeloma
Leukemia (2014)
-
Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience
International Journal of Hematology (2010)
-
Impact of additional cytoreduction following autologous SCT in multiple myeloma
Bone Marrow Transplantation (2008)
-
Impact of early relapse after auto-SCT for multiple myeloma
Bone Marrow Transplantation (2008)
-
Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT
Bone Marrow Transplantation (2008)